Why Is Bausch + Lomb Stock Falling Monday?
Bausch + Lomb stock drops 10% following sudden CEO departure, despite raising full-year 2026 EBITDA guidance.
Stocks · News reference
Bausch Health Announces SILIQ Now Listed Under Alberta's Public Drug Plan For Eligible Moderate To Severe Plaque Psoriasis Patients
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Bausch Health’s Salix Says Cirrhosis Care Pathway Pilot Raised Hepatic Encephalopathy Treatment Rates From 60.2% To 64.9%
Bausch + Lomb Appoints Chairman Thomas J. Appio As Interim CEO, Effective Immediately; Company And Its Parent Bausch Health Expect To Raise FY26 Adjusted EBITDA Guidance, Excluding Acquired IPR&D
Preliminary Update on 2026 Guidance2Based on preliminary third-quarter results, Bausch + Lomb and Bausch Health currently expect to raise full-year 2026 adjusted EBITDA excluding Acquired IPR&D1 guidance.3 The
4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate Hike
With Wall Street experiencing volatility due to Middle East tensions and inflation concerns, the Federal Reserve has raised interest rates for the first time in three years and hints at further hikes. The article recommends four low-beta defensive healthcare stocks as potential investments during this uncertain period: Abbott Laboratories, Corcept Therapeutics, Precigen, and Bausch Health Companies.